Zentalis Pharmaceuticals, Inc.
ZNTL evidence brief
What we can confirm
- BioSniper Score:
- 6.9 / 10
- Market Cap:
- $381.5M
- Lead Asset:
- azenosertib (ZN-c3) (Phase 3)
What it means
What to watch
Prepared research question
What matters most for ZNTL—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ZNTL
Zentalis Pharmaceuticals is a clinical-stage biopharmaceutical company developing azenosertib, a potentially first-in-class WEE1 inhibitor, with a focus on Cyclin E1-positive ovarian cancer and other solid tumors.
Key risk: Limited cash runway
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate · 9 clinical trials for Zentalis Pharmaceuticals, Inc..
Zentalis Pharmaceuticals is a clinical-stage biopharmaceutical company developing azenosertib, a potentially first-in-class WEE1 inhibitor, with a focus on Cyclin E1-positive ovarian cancer and other solid tumors.
- Zentalis is developing azenosertib (ZN-c3), an oral small molecule WEE1 inhibitor, for solid tumors including ovarian cancer and osteosarcoma [pipeline].
- As of June 30, 2026, the company reported cash and equivalents of $24.8M, net income of -$42.3M, and shareholders' equity of $143.6M [sec].
- The DENALI Phase 2 trial of azenosertib in Cyclin E1-positive PROC is ongoing, with topline data anticipated by year end 2026 [news · 2025-11-10].
- Cash runway is estimated to fund operations into late 2027, based on assumptions that may prove imprecise [sec_mda · as of 2026-05-12].
- The company has presented Phase 1b MUIR trial data showing combinability and activity of azenosertib with paclitaxel in an all-comer PROC setting [sec_mda · as of 2026-08-06].
What works
- Azenosertib targets Cyclin E1-positive ovarian cancer, a patient population with significantly worse outcomes, addressing an unmet need [sec_mda · as of 2026-08-06].
- The DENALI Phase 2 trial has the potential to support accelerated approval, subject to FDA feedback, with topline data expected by year end 2026 [news · 2025-11-10].
- Phase 1b MUIR data demonstrated combinability and activity of azenosertib in combination with paclitaxel in PROC patients [sec_mda · as of 2026-08-06].
What to weigh
- The company reported a net loss of $42.3M for the six months ended June 30, 2026, with cash and equivalents of only $24.8M as of that date [sec].
- Cash runway estimates are based on assumptions that may prove imprecise, and the company could utilize capital resources sooner than expected [sec_mda · as of 2026-05-12].
- Azenosertib faces a competitive landscape with 160 competitors, including major pharmaceutical companies like Hoffmann-La Roche [pipeline].
- The company's future funding requirements depend on many uncertain factors, including the progress, costs, and results of clinical trials [sec_mda · as of 2026-05-12].
From the filings
Quoted directly from source documents.
Azenosertib is a WEE1 inhibitor for solid tumors.
“Oral, small molecule WEE1 inhibitor; inhibition of WEE1, a DNA damage response kinase, drives cancer cells into mitosis without being able to repair damaged DNA, resulting in cell death and preventing tumor growth”
Cash runway into late 2027.
“We believe that our existing cash, cash equivalents and marketable securities as of March 31, 2026 will be sufficient to fund our operating expenses and capital expenditure requirements into late 2027.”
SEC MD&A · May 12, 2026
DENALI Phase 2 topline data expected by year end 2026.
“DENALI Phase 2 trial evaluating azenosertib in patients with Cyclin E1-positive PROC remains on track with topline data anticipated by year end 2026”
News · November 10, 2025
Phase 1b MUIR data showed combinability and activity.
“The data showed combinability and activity of azenosertib in an all-comer PROC setting, demonstrating the potential for azenoserti”
SEC MD&A · August 6, 2026
Catalyst timeline
- 2019-11-01 · Phase 1 Start (ZN-c3 single agent) — Initiation of Phase 1 study of ZN-c3 as a single agent in subjects with solid tumors.
- 2020-10-26 · Phase 1b Start (ZN-c3 + chemo/bevacizumab) — Initiation of Phase 1b study of ZN-c3 in combination with chemotherapy or bevacizumab in ovarian, peritoneal, or fallopian tube cancer.
- 2021-07-28 · Phase 2 Start (uterine serous carcinoma) — Initiation of Phase 2 study of ZN-c3 in adult women with recurrent or persistent uterine serous carcinoma.
- 2021-08-01 · Phase 1/2 Start (osteosarcoma) — Initiation of Phase 1/2 study of ZN-c3 in combination with gemcitabine in relapsed or refractory osteosarcoma.
- 2022-01-27 · Phase 2 Start (dose expansion) — Initiation of Phase 1/2 dose-escalation and dose-expansion study.
Risks & what to watch (3)›
Key risks
- Limited cash runway — Cash and equivalents of $24.8M as of June 30, 2026, with net loss of $42.3M, may not sustain operations into late 2027 if assumptions prove wrong [sec].
- Clinical trial uncertainty — DENALI Phase 2 topline data expected by year end 2026, but risks of delay or negative results could impact accelerated approval prospects [news · 2025-11-10].
- Intense competition — Azenosertib faces 160 competitors, including Hoffmann-La Roche, in the WEE1 inhibitor space [pipeline].
What to watch
- Topline data from the DENALI Phase 2 trial of azenosertib in Cyclin E1-positive PROC, expected by year end 2026 [news · 2025-11-10].
- Cash runway updates: as of June 30, 2026, cash and equivalents were $24.8M; monitor future filings for changes in burn rate [sec].
- FDA feedback on potential accelerated approval based on DENALI Part 2 results [news · 2025-11-10].
- Progress of Phase 1b MUIR trial and any additional data presentations for azenosertib in combination with paclitaxel [sec_mda · as of 2026-08-06].
Sources: Catalysts · News · Pipeline · SEC filings · SEC MD&A · Generated October 12, 2026 · How we verify sources →
Run Zentalis Pharmaceuticals, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Zentalis Pharmaceuticals, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.50 · 0% dilution
Lead: Phase 3
1 candidate
No upcoming catalysts tracked
1 buy · 0 sells (180d)
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
102
Total value held
$93.4M
| Holder | Shares | Value |
|---|---|---|
| 5am venture management, llc | 3,947,913 | $9.2M |
| squadron capital management llc | 3,631,000 | $8.5M |
| two sigma investments, lp | 2,956,526 | $6.9M |
| vanguard capital management llc | 2,310,707 | $5.4M |
| renaissance technologies llc | 1,938,145 | $4.5M |
| citadel advisors llc | 1,732,083 | $4.1M |
| d. e. shaw & co., inc. | 1,484,098 | $3.5M |
| opaleye management inc. | 1,412,656 | $3.3M |
| decheng capital llc | 1,323,327 | $3.1M |
| millennium management llc | 1,289,822 | $3.0M |
Showing top 10 of 102 institutional holders of Zentalis Pharmaceuticals, Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 22, 2026- % of float
- 9.6%
- Days to cover
- 1.4
- Shares short
- 5,488,269
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ZNTL short interestGovernance
Frequently asked questions
What is the AI investment thesis for Zentalis Pharmaceuticals, Inc.?
Zentalis Pharmaceuticals is a clinical-stage biopharmaceutical company developing azenosertib, a potentially first-in-class WEE1 inhibitor, with a focus on Cyclin E1-positive ovarian cancer and other solid tumors.
What is Zentalis Pharmaceuticals, Inc.'s lead drug candidate?
Zentalis Pharmaceuticals, Inc.'s most advanced tracked candidate is azenosertib (ZN-c3) (Phase 3) for Solid Tumor; Osteosarcoma; Uterine Serous Carcinoma.
Who is the CEO of Zentalis Pharmaceuticals, Inc.?
Ms. Julie M. Eastland M.B.A. is the chief executive officer of Zentalis Pharmaceuticals, Inc. (ZNTL).
Where is Zentalis Pharmaceuticals, Inc. headquartered?
Zentalis Pharmaceuticals, Inc. (ZNTL) is headquartered in San Diego, CA, United States.
What therapeutic areas does Zentalis Pharmaceuticals, Inc. focus on?
Zentalis Pharmaceuticals, Inc. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.